Study identifier:D961HC00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Nexium capsules Clinical Experience Investigation
gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis,"non-erosive reflux disease, Zollinger-Ellison syndrome
-
No
-
All
3691
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2014 by AstraZeneca
AstraZeneca
-
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal ulcer", "anastomotic ulcer", "reflux oesophagitis", "non-erosive reflux disease", or "Zollinger-Ellison syndrome"
Nexium capsules Clinical Experience Investigation
Arms | Assigned Interventions |
---|---|
Nexium | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.